Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Inventory (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Change in Inventory for 4 consecutive years, with $3.6 million as the latest value for Q4 2025.

  • Quarterly Change in Inventory rose 222.41% to $3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.7 million through Dec 2025, up 1532.8% year-over-year, with the annual reading at $10.7 million for FY2025, 1532.8% up from the prior year.
  • Change in Inventory hit $3.6 million in Q4 2025 for Axsome Therapeutics, down from $5.0 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $5.0 million in Q3 2025 to a low of -$1.7 million in Q3 2023.
  • Historically, Change in Inventory has averaged $1.4 million across 4 years, with a median of $1.2 million in 2023.
  • Biggest five-year swings in Change in Inventory: crashed 681.82% in 2023 and later soared 487.73% in 2025.
  • Year by year, Change in Inventory stood at $1.3 million in 2022, then surged by 269.74% to $4.9 million in 2023, then plummeted by 76.9% to $1.1 million in 2024, then skyrocketed by 222.41% to $3.6 million in 2025.
  • Business Quant data shows Change in Inventory for AXSM at $3.6 million in Q4 2025, $5.0 million in Q3 2025, and $1.8 million in Q2 2025.